Br[C:2]1[S:6][C:5]([C:7]2[CH:12]=[CH:11][N:10]=[C:9]([NH:13][CH:14]3[CH2:19][C:18]([CH3:21])([CH3:20])[NH:17][C:16]([CH3:23])([CH3:22])[CH2:15]3)[N:8]=2)=[CH:4][CH:3]=1.[Li]CCCC.[CH3:29][N:30]1[CH2:35][CH2:34][C:33](=[O:36])[CH2:32][CH2:31]1>C1COCC1>[CH3:29][N:30]1[CH2:35][CH2:34][C:33]([C:2]2[S:6][C:5]([C:7]3[CH:12]=[CH:11][N:10]=[C:9]([NH:13][CH:14]4[CH2:19][C:18]([CH3:21])([CH3:20])[NH:17][C:16]([CH3:23])([CH3:22])[CH2:15]4)[N:8]=3)=[CH:4][CH:3]=2)([OH:36])[CH2:32][CH2:31]1[4-(5-Bromo-thiophen-2-yl)-pyrimidin-2-yl]-(2,2,6,6-tetramethyl-piperidin-4-yl)-amine (Step C of Example 5, 198 mg, 0.5 mmol) was dissolved in THF (10 ml), cooled to −78° C. and treated with nBuLi (1.6M in hexane, 0.94 ml, 1.5 mmol) for 15 minutes. N-methyl-4-piperidone (231 μl, 2 mmol) in THF (0.2 ml) was added rapidly and the reaction mixture stirred for 15 minutes at −78° C., then poured on water and extracted three times with EtOAc. The combined organic phases were dried over sodium sulfate, filtered, evaporated to dryness and purified via preparative HPLC to give the title compound as colorless crystals, which crystallized from ether. Yield: 40 mg (19%).
Wird geladen…